15 results match your criteria Reviews in Contemporary Pharmacotherapy[Journal]

  • Page 1 of 1

Contemporary Management of Direct Oral Anticoagulants During Cardioversion and Ablation for Nonvalvular Atrial Fibrillation.

Pharmacotherapy 2019 Jan 11;39(1):94-108. Epub 2019 Jan 11.

Department of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee, Memphis, Tennessee.

As overall prevalence of atrial fibrillation (AF) continues to rise, the number of patients who undergo ablation, or electrical/chemical cardioversion, to restore normal sinus rhythm continues to increase as well. As direct oral anticoagulants (DOACs) have continued to be incorporated into clinical practice for long-term anticoagulation for AF, experience with how best to manage use of DOACs during electrophysiologic procedures is evolving. This review is intended to provide health care providers with a summary of current evidence regarding the use of DOACs during cardioversion and catheter ablation and provide key considerations for their use during such electrophysiologic procedures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/phar.2205DOI Listing
January 2019
1 Read

Intranasal Ketamine and Its Potential Role in Cancer-Related Pain.

Pharmacotherapy 2018 03 23;38(3):390-401. Epub 2018 Feb 23.

Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.

Cancer-related pain continues to be a significant therapeutic challenge, made more difficult by contemporary opioid use and diversion concerns. Conventional treatment using a tiered approach of nonsteroidal antiinflammatory drugs (NSAIDs), opioids, and adjuvant agents is limited; and alternatives are needed for patients with rapidly progressing pain and those who develop hyperalgesia and tolerance to opioids. Ketamine, an N-methyl-d-aspartate (NMDA) selective antagonist, has historically been used for anesthesia in adult and pediatric populations but has also been investigated for depression, bipolar disorder, and general and postoperative pain management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/phar.2090DOI Listing
March 2018
8 Reads

Cabozantinib: A Multitargeted Oral Tyrosine Kinase Inhibitor.

Pharmacotherapy 2018 03 7;38(3):357-369. Epub 2018 Feb 7.

School of Pharmacy, Duquesne University, Pittsburgh, Pennsylvania.

Cabozantinib is an oral small-molecule multitargeted tyrosine kinase inhibitor (TKI) that may confer an advantage over other TKIs that target a single receptor. It was approved by the U.S. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/phar.2076DOI Listing
March 2018
20 Reads

Trowels and Tribulations: Review of Antimicrobial-Impregnated Bone Cements in Prosthetic Joint Surgery.

Pharmacotherapy 2017 12 17;37(12):1565-1577. Epub 2017 Nov 17.

Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan.

Antimicrobial-impregnated bone cement (AIBC) is a staple of contemporary orthopedic surgery and has been used to either treat or prevent prosthetic joint infection. Applied intraoperatively during primary arthroplasty or prosthetic joint exchange, this drug-delivery vehicle has become a popular means of maximizing drug concentrations within a joint space while minimizing systemic exposure. Antimicrobial characteristics conducive to cement loading include availability of a crystalline powder formulation, molecular characteristics, minimal impact on cement integrity, and other variables promoting drug elution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/phar.2040DOI Listing
December 2017
9 Reads

Therapeutic Management of Familial Hypercholesterolemia: Current and Emerging Drug Therapies.

Pharmacotherapy 2015 Dec;35(12):1189-203

Department of Pharmacy Practice, Thomas Jefferson University, Jefferson College of Pharmacy, Philadelphia, Pennsylvania.

Familial hypercholesterolemia (FH) is a genetic disorder characterized by significantly elevated low-density lipoprotein cholesterol (LDL-C) concentrations that result from mutations of the LDL receptor, apolipoprotein B (apo B-100), and proprotein convertase subtilisin/kexin type 9 (PCSK9). Early and aggressive treatment can prevent premature atherosclerotic cardiovascular disease in these high-risk patients. Given that the cardiovascular consequences of FH are similar to typical hypercholesterolemia, traditional therapies are utilized to decrease LDL-C levels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/phar.1672DOI Listing
December 2015
30 Reads

Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug.

Pharmacotherapy 2015 Dec;35(12):1164-72

Department of Pharmacy, UPMC Presbyterian University Hospital, Pittsburgh, Pennsylvania.

Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disorder characterized by unexplained left ventricular hypertrophy in the absence of other cardiac or systemic etiologies. Approximately two-thirds of patients with HCM develop left ventricular outflow tract (LVOT) obstruction with or without provocation, whereas nearly half develop heart failure with preserved ejection fraction. Medical management of heart failure with preserved ejection fraction is based on the presence of symptoms and LVOT obstruction and frequently includes β-blockers or verapamil. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/phar.1664DOI Listing
December 2015
38 Reads

Pharmacotherapy update of acute idiopathic pericarditis.

Pharmacotherapy 2015 Jan;35(1):99-111

Department of Pharmacy: Clinical and Administrative Sciences, University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma; PGY-2 Cardiology Pharmacy Resident, University of Pittsburgh Medical Center, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania.

Idiopathic (viral) pericarditis is the most common form of pericardial disease in the Western world. Despite the combination of colchicine and nonsteroidal antiinflammatory drugs (NSAIDs) plus aspirin (ASA), considered first-line therapy, the incidence of recurrent pericarditis is ~20-30%. In addition, secondary recurrence without optimal first-line therapy is ~50%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/phar.1527DOI Listing
January 2015
25 Reads

To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.

Pharmacotherapy 2013 May 9;33(5):496-514. Epub 2013 Apr 9.

College of Pharmacy, University of Minnesota, Minneapolis, MN, USA.

Substantial morbidity, mortality, and costs are associated with progressive diabetic kidney disease (DKD). A goal of Healthy People 2020 is to reduce kidney disease attributable to diabetes mellitus and increase the proportion of patients who receive agents that interrupt the renin-angiotensin system (RAS), such as angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs). The mechanisms that contribute to progressive loss of kidney function in patients with diabetes are disrupted by inhibition of the RAS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/phar.1232DOI Listing
May 2013
20 Reads

Importance of direct patient care in advanced pharmacy practice experiences.

Pharmacotherapy 2012 Apr;32(4):e88-97

American College of Clinical Pharmacy, Lenexa, Kansas, USA.

The Accreditation Council for Pharmacy Education issued revised standards (Standards 2007) for professional programs leading to the Doctor of Pharmacy degree in July 2007. The new standards require colleges and schools of pharmacy to provide pharmacy practice experiences that include direct interaction with diverse patient populations. These experiences are to take place in multiple practice environments (e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/j.1875-9114.2012.01110.xDOI Listing
April 2012
14 Reads

Contemporary management of transient ischemic attack: role of the pharmacist.

Authors:
Denise H Rhoney

Pharmacotherapy 2011 Feb;31(2):193-213

Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.

Transient ischemic attacks (TIAs) have been redefined recently. The new tissue-based definition of TIA abandons the 24-hour restriction on symptom duration previously used to differentiate TIA from acute ischemic stroke and requires neuroimaging studies to identify the cause of the ischemia and to determine the presence and extent of brain injury. This new definition brings to light the need for urgent diagnostic testing and timely initiation of treatment, as well as secondary prevention measures to reduce the increased risk of stroke, cardiovascular complications, and death in the days and weeks after a TIA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1592/phco.31.2.193DOI Listing
February 2011
5 Reads

Combination therapy with beta-adrenergic receptor antagonists and phosphodiesterase inhibitors for chronic heart failure.

Pharmacotherapy 2008 Dec;28(12):1523-30

Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT 84112, USA.

Abstract Rational use of phosphodiesterase inhibitors represents an ongoing controversy in contemporary pharmacotherapy for heart failure. In randomized clinical trials, phosphodiesterase inhibitors increased cardiac output at the expense of worsening the rates of sudden cardiac death and cardiovascular mortality. Preliminary findings from ongoing clinical and preclinical investigations of phosphodiesterase activity suggest that combined use of phosphodiesterase inhibitors with beta-adrenergic antagonists may prevent these adverse outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1592/phco.28.12.1523DOI Listing
December 2008
12 Reads

Contemporary issues in clopidogrel therapy: new evidence shaping clinical practice.

Pharmacotherapy 2007 Apr;27(4):553-63

Pharmacy Department, Saint Louis University Hospital, St. Louis, Missouri 63110, USA.

Antiplatelet therapy is a cornerstone in the management of acute coronary syndromes. Clopidogrel produces irreversible inhibition of the platelet adenosine diphosphate receptor, thereby attenuating activation and aggregation of platelets. Clopidogrel has been shown to prevent stent thrombosis in patients undergoing percutaneous coronary intervention (PCI) and reduces major adverse cardiovascular events in patients with unstable angina or non-ST-segment elevation myocardial infarction (non-STEMI). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1592/phco.27.4.553DOI Listing
April 2007
7 Reads

Practical application of nonrandomized research to patient care: a case study of nesiritide.

Pharmacotherapy 2007 Jan;27(1):143-51

Department of Pharmacy Services, Henry Ford Hospital, Detroit, Michigan, USA.

Prospective, randomized clinical trials are the gold standard for establishing cause-and-effect relationships between therapeutic interventions and specific outcomes. Unfortunately, these types of studies are not always available to evaluate important clinical end points such as mortality. Meta-analyses and observational studies are often used in an attempt to fill the gap in the literature when no prospective, randomized trials exist to answer a research question. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1592/phco.27.1.143DOI Listing
January 2007
9 Reads

Anticoagulant prophylaxis in medical patients: an objective assessment.

Pharmacotherapy 2004 Aug;24(8 Pt 2):120S-126S

Ochsner Clinic Foundation, Section of Hospital-Based Internal Medicine, New Orleans, Louisiana 70121, USA.

Venous thromboembolism (VTE) is a clinically silent and potentially fatal disease that manifests as deep vein thrombosis (DVT) and pulmonary embolism. Venous thromboembolism remains a serious public health challenge, with an ever-increasing odds ratio of occurrence given the aging population in the United States. This article reviews the epidemiology of VTE; risk factor identification and stratification as a means of advancing awareness, prevention, and detection of VTE; and prophylaxis options and their outcomes, particularly administration of unfractionated heparin (UFH) 5000 U subcutaneously every 12 versus 8 hours in the at-risk medical patient population. Read More

View Article

Download full-text PDF

Source
August 2004
29 Reads

Acute decompensated heart failure: a contemporary approach to pharmacotherapeutic management.

Pharmacotherapy 2003 Aug;23(8):997-1020

Drug Information Center, Hartford Hospital, Hartford, Connecticut, USA.

Hospital admissions for acute decompensated heart failure (ADHF) have increased precipitously during the past few decades and are projected to continue to increase in the future. To optimize patient outcomes and reduce the costs associated with this disorder, evidenced-based pharmacotherapy is essential. Continuous infusions of loop diuretic therapy rather than bolus dosing may enhance efficacy and reduce the extent of diuretic resistance. Read More

View Article

Download full-text PDF

Source
August 2003
3 Reads
  • Page 1 of 1